Highly active antiretroviral therapy (HAART)-plus: Next steps to enhance HAART in resource-limited areas?

Clinical Infectious Diseases

Volumn 45, Issue 11, 2007, Pages 1499-1501

  Flanigan, Timothy P ^a   Wools Kaloustain, Kara ^b   Harwell, Joseph ^a   Cu Uvin, Susan ^a   Kimaiyo, Sylvester ^c   Carter, E Jane ^a  

^a BROWN UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c MOI UNIVERSITY   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PATIENT CARE; PRIORITY JOURNAL; TUBERCULOSIS; DEVELOPING COUNTRY; DIRECTLY OBSERVED THERAPY; ECONOMICS; HEALTH CARE COST; HEALTH CARE DELIVERY; PATIENT COMPLIANCE; SOCIOECONOMICS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DELIVERY OF HEALTH CARE; DEVELOPING COUNTRIES; DIRECTLY OBSERVED THERAPY; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; SOCIOECONOMIC FACTORS;

EID: 38449085592     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/522992     Document Type: Note

References (9)

1. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-24.
2. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367:1335-42.
3. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: an overview of published literature. J Acquir Immune Defic Syndr 2002; 31(Suppl 3):S123-7.
4. Sow PS, Otieno LF, Bissagnene E, et al. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries. J Acquir Immune Defic Syndr 2007; 44(Suppl 3):262-7.
5. Kumarasamy N, Vallabhaneni S, Cecelia AJ, et al. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr 2006; 41:53-8.
6. Ramadhani H, Thielman N, Landman K, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected persons receiving antiretroviral therapy in Tanzania. Clin Infect Dis 2007; 45:1492-8 (in this issue).
7. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21:965-71.
8. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyeni PN, Bangsber DR. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int J STD AIDS 2005; 16:38-41.
9. Einterz RM, Kimaiyo S, Mengech HNK, et al. Responding to the HIV epidemic: the power of an academic medical partnership. Acad Med 2007; 82:812-8.